The verdict
Our read at a glance.
Whether liraglutide's approved diabetes and weight-management benefits, established in specific products and populations, support the broader or off-label uses often discussed online.
- The signal
- Randomized trials support modest, durable weight loss and better glucose control, with a cardiovascular benefit shown in type 2 diabetes. Saxenda is approved down to age 6 for obesity on the strength of pediatric randomized trials. Head-to-head data show once-weekly semaglutide produces more weight loss than daily liraglutide.
- The unknown
- How liraglutide's smaller effect and daily dosing position it now that more effective weekly agonists are standard, and how settled its long-term benefit and risk are in newer populations such as young children and fatty-liver disease.
- Our read
- Established, but no longer the strongest option. Liraglutide is genuinely approved and well studied for diabetes and weight, so the question is not whether it works but keeping its specific products, doses, and tested populations straight, and not reading newer agonists' results onto it.
The mechanism
How it works.
Liraglutide is a GLP-1 receptor agonist, a synthetic version of the gut hormone GLP-1 carried with a fatty-acid chain that binds albumin in the blood so it lasts about a day instead of minutes. It activates GLP-1 receptors, which prompts the pancreas to release insulin only when blood sugar is high, lowers the counter-regulatory hormone glucagon, slows stomach emptying, and acts on appetite centers in the brain. Those combined actions are why it both lowers blood sugar and reduces food intake.
Safety & regulatory boundary
The consequential part.
Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent data and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Labeling covers pancreatitis, gallbladder disease, and gastrointestinal effects. Victoza (diabetes) and Saxenda (obesity) are distinct products dosed differently, and neither is the same as compounded or research-labeled liraglutide.
What's next
What we're watching.
Pediatric and fatty-liver evidence, real-world comparisons against semaglutide and tirzepatide, and how generic liraglutide entry changes access and product identity.
Context
Why this is discussed.
Liraglutide was the first daily GLP-1 widely used for both type 2 diabetes (Victoza) and obesity (Saxenda), and it stays a reference point as weekly agonists like semaglutide and tirzepatide take over the conversation.
The evidence base
21 cited references.
Regulatory & labels2
Lupin Pharmaceuticals, Inc. (FDA label) · 2025
Biocon Pharma Inc. (FDA label) · 2025
Registered trials7
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2021-03-04
ClinicalTrials.gov · ACTIVE_NOT_RECRUITING · 2021-08-01
ClinicalTrials.gov · PHASE4 · ACTIVE_NOT_RECRUITING · 2024-03-30
ClinicalTrials.gov · PHASE4 · RECRUITING · 2020-11-01
ClinicalTrials.gov · PHASE1/PHASE2 · RECRUITING · 2026-05-10
ClinicalTrials.gov · NA · RECRUITING · 2026-02-13
ClinicalTrials.gov · PHASE4 · ACTIVE_NOT_RECRUITING · 2019-03-18
Indexed literature (PubMed)12
Rubino DM et al. · JAMA · 2022
Moiz A et al. · Ann Intern Med · 2025
Kelly AS et al. · N Engl J Med · 2020
Fox CK et al. · N Engl J Med · 2025
Armstrong MJ et al. · Lancet · 2016
Silver HJ et al. · Diabetes Obes Metab · 2023
Lundgren JR et al. · N Engl J Med · 2021
Blackman A et al. · Int J Obes (Lond) · 2016
Esparham A et al. · Obes Rev · 2024
McGowan B et al. · Nat Med · 2025
García-Casares N et al. · Rev Endocr Metab Disord · 2023
Gudbergsen H et al. · Am J Clin Nutr · 2021
Keep reading